Experience using intra-arterial chemotherapy in combination with MDR-reversing agent for bone and soft-tissue metastases from renal cell carcinoma

Nishinihon Journal of Urology

Volumn 70, Issue 5, 2008, Pages 245-249

  Tsunemori, Hiroyuki ^a   Kitamura, Yuuki ^a   Taniguchi, Susumu ^a   Okazoe, Homare ^a   Taoka, Rikiya ^a   Inui, Masashi ^a   Sugimoto, Mikio ^a   Kakehi, Yoshiyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Intraarterial chemotherapy; MDR; Metastasis; Renal cell carcinoma

Indexed keywords

EID: 44649122766     PISSN: 00290726     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Yagota, A. and Abi-Rached, B.: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22: 42-60, 1995.
2. Hirai, M. et al.: Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J. Pharmacol. Exp. Ther. 275: 73-78, 1995.
3. Japanese source
4. Japanese source
5. Kakehi, Y. et al.: Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J. Urol. 139: 862-865, 1988.
6. Kanamaru, H. et al.: MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J. Natl. Cancer Inst. 81: 844-849, 1989.
7. Akaza, H. et al.: A low-dose combination therapy of interleukin-2 and interferonn-α is effective to lung metastasis of renal cell carcinoma: a multicenter open study. Int. J. Clin. Oncol. 11: 434-440, 2006.
8. Negrier, S. et al.: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cyto-kines: a report from the Groupe Frangais d'lm-munotherapie. Ann. Oncol. 13: 1460-1468, 2002.
9. Atzpodien, J. et al.: Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 88: 348-353, 2003.
10. Toyoda, Y. et al.: Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur. Urol. 52: 163-168, 2007.
11. Chanbner, B. A. and Wilson, W.: Reversal of multidrug resistance. J. Clin. Oncol. 9: 4-6, 1991.